XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMAPDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2026 | $0.54 | 2026-01-02 | 2026-01-02 |
| October 15, 2025 | $0.54 | 2025-10-03 | 2025-10-03 |
| July 15, 2025 | $0.54 | 2025-07-03 | 2025-07-03 |
| April 15, 2025 | $0.54 | 2025-04-03 | 2025-04-03 |
| January 15, 2025 | $0.54 | 2025-01-03 | 2025-01-03 |
Dividends Summary
- Consistent Payer: XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock has rewarded shareholders with 20 dividend payments over the past 5 years.
- Total Returned Value: Investors who held XOMAP shares during this period received a total of $10.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.54/share was paid 8 days ago, on January 15, 2026.
- Payment Schedule: XOMAP currently distributes dividends on a quarterly basis.
- Dividend Growth: Since 2021, the dividend payout has decreased by 25.0%, from $0.72 to $0.54.
- Dividend Reliability: XOMAP has maintained or increased its dividend for 19 consecutive payments.
Company News
Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital ...
XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about January 15, ...
XOMA Royalty Corporation announced an agreement to acquire Generation Bio for $4.2913 per share, with additional contingent value rights for stockholders. The acquisition is expected to close in February 2026 and includes potential milestone and royalty payments.
Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.
Mural Oncology has received High Court approval for a scheme of arrangement where XOMA Royalty will acquire the entire share capital of Mural. The acquisition is expected to become effective on December 5, 2025, with Mural shares to be delisted from Nasdaq on December 4, 2025.
